Zalevsky Jonathan
Chief R&D Officer at NKTR
- Sold, on record
- $4.9M
- Dollars the filings state
- Form 4 sales
- 37
- Latest Nov 17, 2026
- Form 144 notices
- 2
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- NKTRNEKTAR THERAPEUTICSChief R&D Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale NKTRNo planNov 25 2025
Sold 1,157 shares at $54.28 ($63k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 5.7% of holdings ($1.1M position)18,971 shares left0.2x usual sizeFiling
- 2 Form 4 sale NKTRRoutineJan 20 +56 days
Sold 3,867 shares at $35.67 ($138k)
Zalevsky Jonathan, Chief R&D Officer
10b5-1 planSold 15.3% of holdings ($900k position)21,354 shares left0.5x usual sizeFiling
- 3 Form 4 sale NKTRNo planFeb 18 +29 days
Sold 180 shares at $73.00 ($13k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 0.8% of holdings ($1.6M position)21,174 shares left0x usual sizeFiling
- 4 Form 4 sale NKTRNo planMay 19 +90 days
Sold 199 shares at $65.51 ($13k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 0.9% of holdings ($1.4M position)20,975 shares left0.1x usual sizeFiling
- 5 Form 4 sale NKTRRoutineJun 15 +27 days
Sold 5,538 shares at $60.71 ($336k)
Zalevsky Jonathan, Chief R&D Officer
10b5-1 planSold 26.4% of holdings ($1.3M position)15,437 shares left2x usual sizeFiling
- 6 Form 4 sale NKTRRoutineJun 30 +15 days
Sold 5,681 shares at $70.00 ($398k)
Zalevsky Jonathan, Chief R&D Officer
10b5-1 planSold 36.8% of holdings ($1.1M position)9,756 shares left1.5x usual sizeFiling
- 7 Form 4 sale NKTRNo planAug 18 +49 days
Sold 186 shares at $71.98 ($13k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 1.9% of holdings ($702k position)9,570 shares left0x usual sizeFiling
- 8 Form 4 sale NKTRNo planNov 17 +91 days
Sold 192 shares at $35.85 ($7k)
Zalevsky Jonathan, Chief R&D Officer
No 10b5-1 planSold 2% of holdings ($343k position)9,378 shares left0.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (39)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | NKTR | Chief R&D Officer | Form 4 sale | 192 | $7k | 2.0% | No plan | SEC |
| Aug 18, 2026 | NKTR | Chief R&D Officer | Form 4 sale | 186 | $13k | 1.9% | No plan | SEC |
| Jun 30, 2026 | NKTR | Chief R&D Officer | Form 4 sale | 5,681 | $398k | 36.8% | Routine | SEC |
| Jun 15, 2026 | NKTR | Chief R&D Officer | Form 4 sale | 5,538 | $336k | 26.4% | Routine | SEC |
| May 19, 2026 | NKTR | Chief R&D Officer | Form 4 sale | 199 | $13k | 0.9% | No plan | SEC |
| Feb 18, 2026 | NKTR | Chief R&D Officer | Form 4 sale | 180 | $13k | 0.8% | No plan | SEC |
| Jan 20, 2026 | NKTR | Chief R&D Officer | Form 4 sale | 3,867 | $138k | 15.3% | Routine | SEC |
| Nov 25, 2025 | NKTR | Chief R&D Officer | Form 4 sale | 1,157 | $63k | 5.7% | No plan | SEC |
| Sep 4, 2025 | NKTR | Chief R&D Officer | Form 4 sale | 1,721 | $58k | 9.0% | Routine | SEC |
| Sep 2, 2025 | NKTR | Chief R&D Officer | Form 4 sale | 485 | $15k | 2.5% | Routine | SEC |
| Aug 19, 2025 | NKTR | Chief R&D Officer | Form 4 sale | 725 | $19k | 3.6% | No plan | SEC |
| May 19, 2025 | NKTR | Chief R&D Officer | Form 4 sale | 10,712 | $7k | 3.4% | No plan | SEC |
| Feb 19, 2025 | NKTR | Chief R&D Officer | Form 4 sale | 10,300 | $10k | 3.2% | No plan | SEC |
| Dec 19, 2024 | NKTR | Chief R&D Officer | Form 4 sale | 51,115 | $48k | 13.5% | Unusual | SEC |
| Dec 19, 2024 | NKTR | Officer | Form 144 notice | 51,115 | $48k | Notice | SEC | |
| Nov 19, 2024 | NKTR | Chief R&D Officer | Form 4 sale | 7,785 | $8k | 3.1% | No plan | SEC |
| Aug 19, 2024 | NKTR | Chief R&D Officer | Form 4 sale | 6,866 | $9k | 2.7% | No plan | SEC |
| May 17, 2024 | NKTR | Chief R&D Officer | Form 4 sale | 7,355 | $13k | 2.8% | No plan | SEC |
| Feb 20, 2024 | NKTR | Chief R&D Officer | Form 4 sale | 9,014 | $6k | 3.3% | No plan | SEC |
| Nov 17, 2023 | NKTR | Chief R&D Officer | Form 4 sale | 9,646 | $5k | 3.4% | No plan | SEC |
| Nov 17, 2023 | NKTR | Officer | Form 144 notice | 9,646 | $5k | Notice | SEC | |
| Aug 16, 2023 | NKTR | Chief R&D Officer | Form 4 sale | 9,703 | $8k | 3.3% | No plan | SEC |
| May 16, 2023 | NKTR | Chief R&D Officer | Form 4 sale | 9,791 | $7k | 3.2% | No plan | SEC |
| Feb 16, 2023 | NKTR | Chief R&D Officer | Form 4 sale | 10,484 | $31k | 3.3% | Plan not stated | SEC |
| Nov 16, 2022 | NKTR | Chief R&D Officer | Form 4 sale | 13,460 | $48k | 4.1% | Plan not stated | SEC |
| Aug 18, 2022 | NKTR | Chief R&D Officer | Form 4 sale | 73,716 | $343k | 18.4% | Unusual | SEC |
| Aug 16, 2022 | NKTR | Chief R&D Officer | Form 4 sale | 10,560 | $50k | 2.6% | Plan not stated | SEC |
| May 16, 2022 | NKTR | Chief R&D Officer | Form 4 sale | 21,673 | $86k | 7.3% | Plan not stated | SEC |
| Feb 16, 2022 | NKTR | Chief R&D Officer | Form 4 sale | 10,912 | $119k | 3.8% | Plan not stated | SEC |
| Nov 16, 2021 | NKTR | Chief R&D Officer | Form 4 sale | 20,869 | $275k | 8.3% | Plan not stated | SEC |
| Aug 16, 2021 | NKTR | Chief R&D Officer | Form 4 sale | 7,662 | $106k | 3.5% | Plan not stated | SEC |
| May 17, 2021 | NKTR | Chief R&D Officer | Form 4 sale | 31,111 | $569k | 11.7% | Plan not stated | SEC |
| Feb 16, 2021 | NKTR | Chief R&D Officer | Form 4 sale | 24,141 | $540k | 8.3% | Plan not stated | SEC |
| Nov 23, 2020 | NKTR | Chief R&D Officer | Form 4 sale | 16,380 | $269k | 6.1% | Unusual | SEC |
| Nov 16, 2020 | NKTR | Chief R&D Officer | Form 4 sale | 29,618 | $501k | 10.0% | Unusual | SEC |
| Aug 17, 2020 | NKTR | Chief R&D Officer | Form 4 sale | 26,200 | $515k | 8.1% | Unusual | SEC |
| May 18, 2020 | NKTR | Chief R&D Officer | Form 4 sale | 4,558 | $103k | 1.4% | Plan not stated | SEC |
| Feb 18, 2020 | NKTR | Chief R&D Officer | Form 4 sale | 4,774 | $107k | 1.4% | Plan not stated | SEC |
| Nov 18, 2019 | NKTR | Chief R&D Officer | Form 4 sale | 3,960 | $71k | 1.3% | Plan not stated | SEC |